GLP-1 drugs — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become one of the most commonly searched health topics worldwide, and most of that search volume is really a cost and coverage question in disguise: "how much does it cost," "does insurance cover it," "is it available where I live." This article answers that question with real, current, country-by-country figures. It is not medical advice or a treatment recommendation — it's a pricing and policy explainer, since what you'll actually pay depends far more on geography and insurance status than on anything about the drug itself.
The short version: the same class of drug ranges from about $50/month (US Medicare, from July 2026) to $1,350/month (US cash-pay, no insurance) to £122/month (UK NHS, if eligible) to ₹5,660–₹27,500/month (India, no insurance involved) to up to €300/month (Germany, mostly out of pocket) to fully reimbursed (France, for severe obesity, as of June 2026). The gap isn't a pricing error — it's patent status, insurance policy, and national health-system choices colliding.
United States: the widest range of any country
US list prices sit between $1,000 and $1,350 a month before any insurance, with Wegovy retailing as high as $1,349–$1,640/month uninsured. But almost nobody who has any coverage actually pays that. With commercial insurance that covers the drug, manufacturer savings cards can bring the cost down to about $25 per fill. Starting July 1, 2026, CMS will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 a month through the end of 2027. For the uninsured, manufacturer direct-to-consumer programs — NovoCare Pharmacy for Wegovy and LillyDirect for Zepbound — sell the drugs for roughly $199–$449 a month depending on dose.
The catch is that coverage itself is shrinking, not growing. Only 13 states covered GLP-1s for obesity as of early 2026, down from 16 in late 2025, with states citing rising costs. Employers are moving the same direction — more are cutting back GLP-1 coverage in 2026, with further cuts under discussion for 2027. Most plans that do cover it require prior authorization: documented BMI of 30+ (or 27+ with a weight-related condition), evidence of prior lifestyle intervention, and sometimes a specific prescriber type.
United Kingdom: NHS access exists, but it's tightly rationed
The NHS funds GLP-1 weight-loss injections only through a slow, phased rollout. Mounjaro started with the highest-need group — BMI 40+ with at least four weight-related conditions — and widened to BMI 35+ around June 2026; Wegovy remains inside tier-3 specialist weight-management services rather than routine primary care. Where NHS-funded, Mounjaro costs the patient £122 a month at the maximum maintenance dose. But the rollout is genuinely slow: it's planned to reach 250,000 patients over three years, out of roughly 3.4 million who could theoretically qualify, and NHS England has itself acknowledged that full rollout could take up to 12 years. For anyone who doesn't meet the strict eligibility criteria, private prices start around £149/month at the lowest dose and rise to £300–£375/month at the full maintenance dose — a private-price increase of up to 170% seen in late 2025 alone.
India: price is a story about patents, not insurance
India has no public insurance scheme covering GLP-1 weight-loss drugs, so the entire price story here comes down to patent status and generic competition. Mounjaro (tirzepatide) was launched in India by Eli Lilly in March 2025, remains under patent until around 2036, and has no Indian generic — pricing runs from about ₹13,125/month at the 2.5mg starter dose up to ₹25,781/month at the 15mg maximum dose. Wegovy tells the opposite story: facing competition from 10+ Indian semaglutide generic brands, Novo Nordisk cut Wegovy's India price sharply, effective April 2026, to roughly ₹5,660–₹16,400/month depending on dose — a fraction of what the same drug costs in the US or UK, purely because generic competition exists for semaglutide but not yet for tirzepatide.
Germany and France: two EU countries, two completely different answers
Germany's statutory health insurance excludes drugs used purely for weight loss, treating them as lifestyle medications rather than medical necessities — most German patients pay out of pocket, up to €300 a month, with only a narrow exception since early 2024 for Wegovy when obesity poses serious cardiovascular risk. France has taken the opposite path: on May 28, 2026, France's Health Ministry confirmed that Wegovy and Mounjaro would be reimbursed through the French public health system for severe obesity, effective June 15, 2026 — the first such reimbursement decision for anti-obesity GLP-1 drugs anywhere in the European Union. Two large EU economies, same drug class, opposite coverage policies, decided independently.
| Country | Typical monthly cost | What drives it |
|---|---|---|
| United States | $25 (insured, savings card) – $50 (Medicare, from Jul 2026) – $1,350 (uninsured cash price) | Insurance status; state/employer coverage shrinking in 2026 |
| United Kingdom | £122 (NHS, if eligible) – £300–£375 (private) | NHS phased rollout by BMI/comorbidity tier; full access could take 12 years |
| India | ₹5,660–₹16,400 (Wegovy) – ₹13,125–₹25,781 (Mounjaro) | Generic competition for semaglutide; no generic yet for tirzepatide (patent to ~2036) |
| Germany | Up to €300 (mostly out of pocket) | Statutory insurance excludes weight-loss-only use, narrow cardiovascular exception |
| France | Reimbursed for severe obesity (from Jun 15, 2026) | First EU country to publicly reimburse GLP-1s for obesity |
What actually explains the gap
Three separate forces stack on top of each other, and it's worth separating them because they call for different expectations going forward. Patent status explains India's split between a cheap Wegovy and an expensive Mounjaro — generics only exist where the patent has room to be challenged or where a manufacturer chooses aggressive local pricing. Insurance and reimbursement policy explains the US/UK/Germany/France differences — each is a national or employer-level decision about whether weight-loss treatment counts as coverable medical necessity, made independently and revisable at any time (as the US state-coverage pullback in 2026 shows). List price versus negotiated price explains why "the US price" is almost meaningless as a single number — the same drug has at least four different real prices depending on Medicare, commercial insurance, savings programs, or cash pay.
What this means if you're budgeting for treatment
- Get your actual coverage answer directly — from your insurer's formulary, your employer's benefits team, or (in the UK/France) your national health service's current eligibility criteria — since general figures like these can't account for your specific plan.
- Ask about manufacturer savings programs before assuming the list price applies — in the US in particular, the gap between list price and what insured patients actually pay is enormous.
- Budget for an ongoing monthly cost, not a one-time expense — these are long-term treatments, and the WHO's own guideline frames them as requiring continuous, multi-year use, not a short course.
None of this is a recommendation for or against treatment — that decision, and which specific drug might suit you, belongs with your own doctor.